The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Oncology Adjuvants-Global Market Insights and Sales Trends 2025
Synopsis
Oncology adjuvants are substances or therapies used in combination with primary cancer treatments, such as surgery, chemotherapy, or radiation therapy, to enhance their efficacy or reduce the risk of cancer recurrence.
The global Oncology Adjuvants market size is expected to reach US$ 599 million by 2029, growing at a CAGR of 3.5% from 2023 to 2029. The market is mainly driven by the significant applications of Oncology Adjuvants in various end use industries. The expanding demands from the Cancer Research Institutes and Cancer Hospitals, are propelling Oncology Adjuvants market. Radiotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at % CAGR for the next seven-year period.
The market for oncology adjuvants is driven by the need for improved cancer treatment outcomes and the demand for personalized and targeted cancer therapies. The market's growth is also influenced by ongoing research in cancer immunotherapy and the development of novel adjuvant therapies.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Oncology Adjuvants, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Oncology Adjuvants market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Oncology Adjuvants market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Oncology Adjuvants sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Oncology Adjuvants covered in this report include Eli Lilly, Amgen, BMS, Biogen, Sanofi, AstraZeneca, Pfizer, Hengrui Medicine and Hisun Pharmaceutical, etc.
The global Oncology Adjuvants market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Eli Lilly
Amgen
BMS
Biogen
Sanofi
AstraZeneca
Pfizer
Hengrui Medicine
Hisun Pharmaceutical
Yibai Pharmaceutical
SL Pharmaceutical
Zhendong Pharmaceutical
Main Luck Pharmaceuticals
Sanjiu Medical
Livzon Pharmaceutical
Global Oncology Adjuvants market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Oncology Adjuvants market, Segment by Type:
Radiotherapy
Chemotherapy
Immunotherapy
Hormone therapy
Targeted therapy
Global Oncology Adjuvants market, by Application
Cancer Research Institutes
Cancer Hospitals
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Oncology Adjuvants manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Oncology Adjuvants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Oncology adjuvants are substances or therapies used in combination with primary cancer treatments, such as surgery, chemotherapy, or radiation therapy, to enhance their efficacy or reduce the risk of cancer recurrence.
The global Oncology Adjuvants market size is expected to reach US$ 599 million by 2029, growing at a CAGR of 3.5% from 2023 to 2029. The market is mainly driven by the significant applications of Oncology Adjuvants in various end use industries. The expanding demands from the Cancer Research Institutes and Cancer Hospitals, are propelling Oncology Adjuvants market. Radiotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at % CAGR for the next seven-year period.
The market for oncology adjuvants is driven by the need for improved cancer treatment outcomes and the demand for personalized and targeted cancer therapies. The market's growth is also influenced by ongoing research in cancer immunotherapy and the development of novel adjuvant therapies.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Oncology Adjuvants, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Oncology Adjuvants market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Oncology Adjuvants market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Oncology Adjuvants sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Oncology Adjuvants covered in this report include Eli Lilly, Amgen, BMS, Biogen, Sanofi, AstraZeneca, Pfizer, Hengrui Medicine and Hisun Pharmaceutical, etc.
The global Oncology Adjuvants market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Eli Lilly
Amgen
BMS
Biogen
Sanofi
AstraZeneca
Pfizer
Hengrui Medicine
Hisun Pharmaceutical
Yibai Pharmaceutical
SL Pharmaceutical
Zhendong Pharmaceutical
Main Luck Pharmaceuticals
Sanjiu Medical
Livzon Pharmaceutical
Global Oncology Adjuvants market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Oncology Adjuvants market, Segment by Type:
Radiotherapy
Chemotherapy
Immunotherapy
Hormone therapy
Targeted therapy
Global Oncology Adjuvants market, by Application
Cancer Research Institutes
Cancer Hospitals
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Oncology Adjuvants manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Oncology Adjuvants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Oncology Adjuvants Market Overview
1.1 Oncology Adjuvants Product Overview
1.2 Oncology Adjuvants Market Segment by Type
1.2.1 Radiotherapy
1.2.2 Chemotherapy
1.2.3 Immunotherapy
1.2.4 Hormone therapy
1.2.5 Targeted therapy
1.3 Global Oncology Adjuvants Market Size by Type
1.3.1 Global Oncology Adjuvants Market Size Overview by Type (2018-2029)
1.3.2 Global Oncology Adjuvants Historic Market Size Review by Type (2018-2023)
1.3.3 Global Oncology Adjuvants Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Oncology Adjuvants Sales Breakdown by Type (2018-2023)
1.4.2 Europe Oncology Adjuvants Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Oncology Adjuvants Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Oncology Adjuvants Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Oncology Adjuvants Sales Breakdown by Type (2018-2023)
2 Global Oncology Adjuvants Market Competition by Company
2.1 Global Top Players by Oncology Adjuvants Sales (2018-2023)
2.2 Global Top Players by Oncology Adjuvants Revenue (2018-2023)
2.3 Global Top Players by Oncology Adjuvants Price (2018-2023)
2.4 Global Top Manufacturers Oncology Adjuvants Manufacturing Base Distribution, Sales Area, Product Type
2.5 Oncology Adjuvants Market Competitive Situation and Trends
2.5.1 Oncology Adjuvants Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Oncology Adjuvants Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Oncology Adjuvants as of 2022)
2.7 Date of Key Manufacturers Enter into Oncology Adjuvants Market
2.8 Key Manufacturers Oncology Adjuvants Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Oncology Adjuvants Status and Outlook by Region
3.1 Global Oncology Adjuvants Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Oncology Adjuvants Historic Market Size by Region
3.2.1 Global Oncology Adjuvants Sales in Volume by Region (2018-2023)
3.2.2 Global Oncology Adjuvants Sales in Value by Region (2018-2023)
3.2.3 Global Oncology Adjuvants Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Oncology Adjuvants Forecasted Market Size by Region
3.3.1 Global Oncology Adjuvants Sales in Volume by Region (2024-2029)
3.3.2 Global Oncology Adjuvants Sales in Value by Region (2024-2029)
3.3.3 Global Oncology Adjuvants Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Oncology Adjuvants by Application
4.1 Oncology Adjuvants Market Segment by Application
4.1.1 Cancer Research Institutes
4.1.2 Cancer Hospitals
4.2 Global Oncology Adjuvants Market Size by Application
4.2.1 Global Oncology Adjuvants Market Size Overview by Application (2018-2029)
4.2.2 Global Oncology Adjuvants Historic Market Size Review by Application (2018-2023)
4.2.3 Global Oncology Adjuvants Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Oncology Adjuvants Sales Breakdown by Application (2018-2023)
4.3.2 Europe Oncology Adjuvants Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Oncology Adjuvants Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Oncology Adjuvants Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Oncology Adjuvants Sales Breakdown by Application (2018-2023)
5 North America Oncology Adjuvants by Country
5.1 North America Oncology Adjuvants Historic Market Size by Country
5.1.1 North America Oncology Adjuvants Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Oncology Adjuvants Sales in Volume by Country (2018-2023)
5.1.3 North America Oncology Adjuvants Sales in Value by Country (2018-2023)
5.2 North America Oncology Adjuvants Forecasted Market Size by Country
5.2.1 North America Oncology Adjuvants Sales in Volume by Country (2024-2029)
5.2.2 North America Oncology Adjuvants Sales in Value by Country (2024-2029)
6 Europe Oncology Adjuvants by Country
6.1 Europe Oncology Adjuvants Historic Market Size by Country
6.1.1 Europe Oncology Adjuvants Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Oncology Adjuvants Sales in Volume by Country (2018-2023)
6.1.3 Europe Oncology Adjuvants Sales in Value by Country (2018-2023)
6.2 Europe Oncology Adjuvants Forecasted Market Size by Country
6.2.1 Europe Oncology Adjuvants Sales in Volume by Country (2024-2029)
6.2.2 Europe Oncology Adjuvants Sales in Value by Country (2024-2029)
7 Asia-Pacific Oncology Adjuvants by Region
7.1 Asia-Pacific Oncology Adjuvants Historic Market Size by Region
7.1.1 Asia-Pacific Oncology Adjuvants Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Oncology Adjuvants Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Oncology Adjuvants Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Oncology Adjuvants Forecasted Market Size by Region
7.2.1 Asia-Pacific Oncology Adjuvants Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Oncology Adjuvants Sales in Value by Region (2024-2029)
8 Latin America Oncology Adjuvants by Country
8.1 Latin America Oncology Adjuvants Historic Market Size by Country
8.1.1 Latin America Oncology Adjuvants Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Oncology Adjuvants Sales in Volume by Country (2018-2023)
8.1.3 Latin America Oncology Adjuvants Sales in Value by Country (2018-2023)
8.2 Latin America Oncology Adjuvants Forecasted Market Size by Country
8.2.1 Latin America Oncology Adjuvants Sales in Volume by Country (2024-2029)
8.2.2 Latin America Oncology Adjuvants Sales in Value by Country (2024-2029)
9 Middle East and Africa Oncology Adjuvants by Country
9.1 Middle East and Africa Oncology Adjuvants Historic Market Size by Country
9.1.1 Middle East and Africa Oncology Adjuvants Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Oncology Adjuvants Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Oncology Adjuvants Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Oncology Adjuvants Forecasted Market Size by Country
9.2.1 Middle East and Africa Oncology Adjuvants Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Oncology Adjuvants Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Eli Lilly
10.1.1 Eli Lilly Company Information
10.1.2 Eli Lilly Introduction and Business Overview
10.1.3 Eli Lilly Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Eli Lilly Oncology Adjuvants Products Offered
10.1.5 Eli Lilly Recent Development
10.2 Amgen
10.2.1 Amgen Company Information
10.2.2 Amgen Introduction and Business Overview
10.2.3 Amgen Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Amgen Oncology Adjuvants Products Offered
10.2.5 Amgen Recent Development
10.3 BMS
10.3.1 BMS Company Information
10.3.2 BMS Introduction and Business Overview
10.3.3 BMS Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.3.4 BMS Oncology Adjuvants Products Offered
10.3.5 BMS Recent Development
10.4 Biogen
10.4.1 Biogen Company Information
10.4.2 Biogen Introduction and Business Overview
10.4.3 Biogen Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Biogen Oncology Adjuvants Products Offered
10.4.5 Biogen Recent Development
10.5 Sanofi
10.5.1 Sanofi Company Information
10.5.2 Sanofi Introduction and Business Overview
10.5.3 Sanofi Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Sanofi Oncology Adjuvants Products Offered
10.5.5 Sanofi Recent Development
10.6 AstraZeneca
10.6.1 AstraZeneca Company Information
10.6.2 AstraZeneca Introduction and Business Overview
10.6.3 AstraZeneca Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.6.4 AstraZeneca Oncology Adjuvants Products Offered
10.6.5 AstraZeneca Recent Development
10.7 Pfizer
10.7.1 Pfizer Company Information
10.7.2 Pfizer Introduction and Business Overview
10.7.3 Pfizer Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Pfizer Oncology Adjuvants Products Offered
10.7.5 Pfizer Recent Development
10.8 Hengrui Medicine
10.8.1 Hengrui Medicine Company Information
10.8.2 Hengrui Medicine Introduction and Business Overview
10.8.3 Hengrui Medicine Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Hengrui Medicine Oncology Adjuvants Products Offered
10.8.5 Hengrui Medicine Recent Development
10.9 Hisun Pharmaceutical
10.9.1 Hisun Pharmaceutical Company Information
10.9.2 Hisun Pharmaceutical Introduction and Business Overview
10.9.3 Hisun Pharmaceutical Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Hisun Pharmaceutical Oncology Adjuvants Products Offered
10.9.5 Hisun Pharmaceutical Recent Development
10.10 Yibai Pharmaceutical
10.10.1 Yibai Pharmaceutical Company Information
10.10.2 Yibai Pharmaceutical Introduction and Business Overview
10.10.3 Yibai Pharmaceutical Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Yibai Pharmaceutical Oncology Adjuvants Products Offered
10.10.5 Yibai Pharmaceutical Recent Development
10.11 SL Pharmaceutical
10.11.1 SL Pharmaceutical Company Information
10.11.2 SL Pharmaceutical Introduction and Business Overview
10.11.3 SL Pharmaceutical Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.11.4 SL Pharmaceutical Oncology Adjuvants Products Offered
10.11.5 SL Pharmaceutical Recent Development
10.12 Zhendong Pharmaceutical
10.12.1 Zhendong Pharmaceutical Company Information
10.12.2 Zhendong Pharmaceutical Introduction and Business Overview
10.12.3 Zhendong Pharmaceutical Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Zhendong Pharmaceutical Oncology Adjuvants Products Offered
10.12.5 Zhendong Pharmaceutical Recent Development
10.13 Main Luck Pharmaceuticals
10.13.1 Main Luck Pharmaceuticals Company Information
10.13.2 Main Luck Pharmaceuticals Introduction and Business Overview
10.13.3 Main Luck Pharmaceuticals Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Main Luck Pharmaceuticals Oncology Adjuvants Products Offered
10.13.5 Main Luck Pharmaceuticals Recent Development
10.14 Sanjiu Medical
10.14.1 Sanjiu Medical Company Information
10.14.2 Sanjiu Medical Introduction and Business Overview
10.14.3 Sanjiu Medical Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Sanjiu Medical Oncology Adjuvants Products Offered
10.14.5 Sanjiu Medical Recent Development
10.15 Livzon Pharmaceutical
10.15.1 Livzon Pharmaceutical Company Information
10.15.2 Livzon Pharmaceutical Introduction and Business Overview
10.15.3 Livzon Pharmaceutical Oncology Adjuvants Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Livzon Pharmaceutical Oncology Adjuvants Products Offered
10.15.5 Livzon Pharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Oncology Adjuvants Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Oncology Adjuvants Industrial Chain Analysis
11.4 Oncology Adjuvants Market Dynamics
11.4.1 Oncology Adjuvants Industry Trends
11.4.2 Oncology Adjuvants Market Drivers
11.4.3 Oncology Adjuvants Market Challenges
11.4.4 Oncology Adjuvants Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Oncology Adjuvants Distributors
12.3 Oncology Adjuvants Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
